Offer - Urjas Oil for just ₹ 1 X
Cadicrit is a prescription drug, available for use as Injection. It is primarily used for the treatment of Anemia. Other than this, Cadicrit has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Cadicrit is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Detailed information has been provided in the dosage section.
Besides the aforementioned side effects, there are other adverse effects of Cadicrit as well, which are listed below. Normally, these side effects of Cadicrit are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
In addition, Cadicrit's effect is Moderate during pregnancy and Moderate for lactating mothers. Further, the section on Cadicrit related warnings talks about Cadicrit's effects on the liver, heart and kidney.
Cadicrit is contraindicated in people with pre-existing medical conditions like High Blood Pressure, Seizures as it can result in adverse effects. Some other conditions that can be affected by Cadicrit are listed in the contraindications section below.
Drug reaction of Cadicrit with other medicines has been reported. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Cadicrit is considered not safe while driving, and is not addictive.
Cadicrit is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Is the use of Cadicrit safe for pregnant women?
Cadicrit can have harmful effects in pregnant women. If you experience any discomfort after using Cadicrit, then discontinue the use and take your doctor's advice.
Is the use of Cadicrit safe during breastfeeding?
If you are breastfeeding, you may experience some harmful effects of Cadicrit. In case you experience any of these, discontinue its use until you consult your doctor.
What is the effect of Cadicrit on the Kidneys?
Cadicrit rarely harms the kidneys.
What is the effect of Cadicrit on the Liver?
Cadicrit is rarely harmful for the liver.
What is the effect of Cadicrit on the Heart?
There may be an adverse effect on the heart after taking Cadicrit. If you observe any side effects on your body then stop taking this drug. Restart this medicine only if your doctor advises you to do so.
Cadicrit should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Cadicrit unless your doctor advises you to do so -
Is this Cadicrit habit forming or addictive?
No, you will not get addicted to Cadicrit.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Cadicrit. So it is best to avoid driving.
Is it safe?
Cadicrit is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Cadicrit is not used to treat mental disorders.
Interaction between Food and Cadicrit
Due to the absence of research, it is difficult to say how Cadicrit and food will interact.
Interaction between Alcohol and Cadicrit
No research has been done on this till date. Therefore, it is not known what the effect of taking Cadicrit with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Epogen® (Epoetin alfa)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 611